Early antiretroviral therapy reduces the risk of infection-related cancers
HIV in the brain: new tools and treatment to keep your mind beautiful
Removing clinic barriers to rapid initiation of ART in Uganda enables 70% to start on the same day
Dolutegravir safe and highly effective in older children
Long-acting PrEP injection tolerable and acceptable for male volunteers, but dose adjustment needed
Tenofovir alafenamide PrEP protects monkeys from infection, but rectal and vaginal levels in humans may be too low
TAF/emtricitabine maintains viral suppression as well as TDF regimens with less bone and kidney toxicity
PopART trial shows feasibility of reaching 90-90-90 targets for testing and treatment coverage in Zambia and South Africa
Botswana close to reaching the 90-90-90 testing and treatment targets
